Trial reportScience translational medicine2019
Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa.
Open access · greenAbstract readRandomized Controlled Trial
In one paragraph
Trial report in Science translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 2 pooled it
4.6field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 2 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- Meta-analysis of Pregnancy Events in Biomedical HIV Prevention Trials in Sub-Saharan Africa: Implications for Gender Transformative Trials.AIDS and behavior · 2024Pooled it
- Baseline host determinants of robust human HIV-1 vaccine-induced immune responses: A meta-analysis of 26 vaccine regimens.EBioMedicine · 2022Pooled it
- Effects of sex but not race and geographic origin on vaccine-induced HIV-specific antibody responses.Frontiers in immunology · 2025Trial
- Trial
- Analysis of the HIV Vaccine Trials Network 702 Phase 2b-3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk.The Journal of infectious diseases · 2022Trial
- Th2-Biased Transcriptional Profile Predicts HIV Envelope-Specific Polyfunctional CD4Journal of immunology (Baltimore, Md. : 1950) · 2022Trial
- Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults.The New England journal of medicine · 2021Trial
- Comparing HIV Vaccine Immunogenicity Across Trials With Different Populations and Study Designs.Statistics in medicine · 2026Article
- The RV144 Trial Might Still Yield Useful Information.Current HIV research · 2026Review
- Glycan-reactive antibodies isolated from human HIV-1 vaccine trial participants show broad pathogen cross-reactivity.Journal of virology · 2025Article
- A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials.Emerging microbes & infections · 2025Article
- Evaluating the Immune Response in Rabbits to an Escalating Dose of mRNA-Based HIV-1 Env Immunogens.Vaccines · 2025Article
- Review
- A Pentavalent HIV-1 Subtype C Vaccine Containing Computationally Selected gp120 Strains Improves the Breadth of V1V2 Region Responses.Vaccines · 2025Article
- ALVAC-prime and monomeric gp120 protein boost induces distinct HIV-1 specific humoral and cellular responses compared with adenovirus-prime and trimeric gp140 protein boost.PLOS global public health · 2025Article
- Potent broadly neutralizing antibodies mediate efficient antibody-dependent phagocytosis of HIV-infected cells.PLoS pathogens · 2024Article
- Review
- Flt3 agonist enhances immunogenicity of arenavirus vector-based simian immunodeficiency virus vaccine in macaques.Journal of virology · 2024Article
- Differences in neutralizing antibody sensitivities and envelope characteristics indicate distinct antigenic properties of Nigerian HIV-1 subtype G and CRF02_AG.Virology journal · 2024Article
- Exploring HIV Vaccine Progress in the Pre-Clinical and Clinical Setting: From History to Future Prospects.Viruses · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors at 13 institutions in 2 countries.
Glenda E GrayPerinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 1864, South Africa. glenda.gray@mrc.ac.za.ORCID 0000-0003-4649-1477
Ying HuangVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.ORCID 0000-0002-9655-7502
Nicole GrunenbergVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.ORCID 0000-0003-2565-3879
Fatima LaherPerinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 1864, South Africa.ORCID 0000-0001-5231-9951
Surita RouxThe Desmond Tutu HIV Centre, University of Cape Town, Cape Town 8001, South Africa.ORCID 0000-0001-7621-6762
Erica Andersen-NissenVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Stephen C De RosaVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Britta FlachCape Town HVTN Immunology Laboratory, Hutchinson Centre Research Institute of South Africa, Cape Town 8001, South Africa.
April K RandhawaVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.ORCID 0000-0003-2652-3734
Ryan JensenVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.ORCID 0000-0002-0139-801X
Edith M SwannVaccine Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20852, USA.ORCID 0000-0001-7791-9232
Linda-Gail BekkerThe Desmond Tutu HIV Centre, University of Cape Town, Cape Town 8001, South Africa.
Craig InnesThe Aurum Institute, Klerksdorp 2570, South Africa.
Erica LazarusPerinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 1864, South Africa.ORCID 0000-0002-4965-0624
Lynn MorrisNational Institute for Communicable Diseases, National Health Laboratory Service, Sandringham, Johannesburg 2192, South Africa.ORCID 0000-0003-3961-7828
Nonhlanhla N MkhizeNational Institute for Communicable Diseases, National Health Laboratory Service, Sandringham, Johannesburg 2192, South Africa.ORCID 0000-0003-3037-1243
Guido FerrariDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
David C MontefioriDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0003-0856-6319
Xiaoying ShenDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Sheetal SawantDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0002-1109-7907
Nicole YatesDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0003-2678-1311
John HuralVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Abby IsaacsVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.ORCID 0000-0003-4139-6964
Sanjay PhogatSanofi Pasteur, Swiftwater, PA 18370, USA.
Carlos A DiazGranadosSanofi Pasteur, Swiftwater, PA 18370, USA.
Carter LeeGlobal Solutions for Infectious Diseases, South San Francisco, CA 94080, USA.
Faruk SinangilGlobal Solutions for Infectious Diseases, South San Francisco, CA 94080, USA.
Nelson L MichaelUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.ORCID 0000-0001-5882-5548
Merlin L RobbUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.ORCID 0000-0003-3949-9649
James G KublinVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.ORCID 0000-0003-1279-3741
Peter B GilbertVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.ORCID 0000-0002-2662-9427
M Juliana McElrathVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.ORCID 0000-0003-2276-7117
Georgia D TomarasDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Lawrence CoreyVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.ORCID 0000-0002-2179-2436
Fred Hutch Cancer Center · USDuke University · USDesmond Tutu HIV Foundation · ZAGlobal Solutions for Infectious Diseases · USNational Health Laboratory Service · ZAPerinatal HIV Research Unit · ZASanofi (United States) · USWalter Reed Army Institute of Research · USAurum Institute · ZACape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa · ZANational Institute of Allergy and Infectious Diseases · USResearch ICT Africa · ZASouth African Medical Research Council · ZA
Funding
LOC: HIV Vaccine Trials NetworkUM1AI068614 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Dan H. Barouch, Lawrence Corey · 2011 to 2026
$1175.6MLC: HIV Vaccine Trials NetworkUM1AI068618 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Margaret Juliana McElrath · 2011 to 2026
$483.6MSDMC: HIV Vaccine Trials NetworkUM1AI068635 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert, Yunda Huang · 2011 to 2026
$385.9MSocial and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI Nwora Lance Okeke · 2005 to 2026
$50.5MSoweto Clinical Trials UnitUM1AI069453 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI Glenda E Gray, Lerato Mohapi · 2012 to 2026
$40.9MUniversity of KwaZulu-Natal - CAPRISA HIV/AIDS Clinical Trials UnitUM1AI069469 · NIAID · UNIVERSITY OF KWAZULU-NATAL · PI QUARRAISHA ABDOOL KARIM · 2012 to 2026
$36.4MUniversity of Cape Town Clinical Trials Unit (UCTCTU)UM1AI069519 · NIAID · UNIVERSITY OF CAPE TOWN · PI Linda-Gail Bekker · 2012 to 2026
$36.3MSoweto Clinical Trials UnitU01AI069453 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI GRAY, GLENDA · 2007 to 2011
$25.5MDeveloping appropriate risk reduction interventions for pre-teensR21MH083308 · NIMH · WITS HEALTH CONSORTIUM (PTY), LTD · PI GRAY, GLENDA E, SIKKEMA, KATHLEEN J · 2008 to 2009
$331kNIAID NIH HHS P30 AI064518NIAID NIH HHS U01 AI069453NIAID NIH HHS UM1 AI068614NIAID NIH HHS UM1 AI068618NIAID NIH HHS UM1 AI068635NIAID NIH HHS UM1 AI069453NIAID NIH HHS UM1 AI069469NIAID NIH HHS UM1 AI069519NIMH NIH HHS R21 MH083308
Abstract
One of the most successful HIV vaccines to date, the RV144 vaccine tested in Thailand, demonstrated correlates of protection including cross-clade V1V2 immunoglobulin G (IgG) breadth, Env-specific CD4
Indexed as
AdultAIDS VaccinesAntibody-Dependent Cell CytotoxicityAntibody FormationCD40 LigandFemaleHIV AntibodiesHIV AntigensHumansImmunity, HumoralImmunoglobulin GInterferon-gammaInterleukin-2MaleNeutralization TestsPhagocytosisAIDS VaccinesCD40 LigandHIV AntibodiesHIV AntigensImmunoglobulin GInterferon-gammaInterleukin-2Placebos
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.